Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for LANTUS
- Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
- SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)
- A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
- A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
- Difference of Basal Insulin Titration Method in Reducing HbA1c Among Type 2 Diabetes Mellitus (T2DM) Patients.
- A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
- Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
- The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus
- A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine
- Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients
- A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
- A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients
- Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients
- A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes
- Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
- Mylan Insulin Aspart Study
- Remission Through Early Monitored Insulin Therapy - Duration Month
- Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
- Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus
- A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
- Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
- Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients
- "Physiological" Insulin Scheme vs Traditional Scheme for Glycemic Control in Non-critical Hospitalized Patients With Diabetes Mellitus 2
- A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
- A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
- A Trial Comparing Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
- Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
- Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
- Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
- Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
- Environmental Effects Type 1 Diabetes Mellitus
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
- Glargine U300 Hospital Trial
- Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
- A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
- GLP-1/Basal Insulin Combination Therapy
- Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
- Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
- Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
- Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
- Sitagliptin in Non-Diabetic Patients Undergoing General Surgery
- Randomized Sitagliptin Withdrawal Study (MK-0431-845)
- Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
- Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
- A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
- Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
- Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
- Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke
- Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens
- Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
- Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes
- Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes
- A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes
- PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes
- Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
- Fatty Liver Study in Patients With Type II Diabetes
- Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)
- Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
- Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
- A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
- Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
- Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
- Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
- The Inova Type 2 Diabetes Mellitus Study
- Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM
- Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus
- Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
- Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia
- Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting
- Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
- Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
- ADA Linagliptin in Long Term Care
- The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)
- A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
- Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment
- Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
- Liraglutide Hospital Discharge Trial
- Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
- Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM
- Comparison Study of Insulin Glargine and NPH Insulin
- Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
- Cost Effectiveness of Glargine Insulin Versus NPH Insulin
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
- Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients
- A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
- Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
- Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
- A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
- Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
- Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia
- A Study of LY2963016 in Healthy Participants
- A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
- Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
- Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
- Simplified Insulin Protocol Using Lantus in Elderly
- Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
- A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
- Comparing Long-acting Insulins During Exercise in Type 1 Diabetes
- Health Care for Type 1 Diabetes in Developing World
- A Study in Adults With Type 2 Diabetes
- A Study in Adults With Type 1 Diabetes
- Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
- Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes
- A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects
- Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
- Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment
- Pharmacist Intervention for Glycemic Control in The Community
- Carbohydrate Consumption as a Factor in Aspart Dosing
- Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis
- JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients
- Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
- New Onset Type 1 Diabetes: Role of Exenatide
- Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes
- Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
- Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
- Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.
- Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
- baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
- Apidra Children & Adolescents Study
- Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
- Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
- Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus
- Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
- Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)
- Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
- Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial
- Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin
- Diabetes in the Elderly: Prospective Study
- Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
- Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine
- Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting
- Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
- Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)
- Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes
- Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes
- Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
- Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment
- Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
- Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
- Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
- Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
- An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus
- An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus
- Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes
- Levemir-Body Composition and Energy Metabolism
- Evaluation of Exenatide in Patients With Diabetic Neuropathy
- Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
- Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control
- Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
- Endothelial Effects of Basal Insulin: Detemir Versus Glargine
- Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
- Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay
- Insulin Glargine Versus Twice-Daily NPH
- Insulin Glargine at Bedtime or in AM Versus NPH
- Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction
- Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)
- Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes
- Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
- Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)
- Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes
- Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
- Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
- Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
- Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)
- An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice
- Characteristics of Glargine in Type 2 Diabetics
- Basal Insulins - Pharmacodynamics
- Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus
- Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH
- Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)
- Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide
- Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes
- Glycemic Optimization Treatment Study
- Lispro Mix 25 vs. Glargine in Type 2 Diabetics
- Glulisine + Lantus in Type I Patients
- Glulisine + Lantus in Type I Patients
- PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro
- Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus
- Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
- A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine
- An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
- DOMME Dose Optimization Multicentric Mexican Evaluation
- Insulin Secretion in Diabetes Before and After Glycemic Control
- Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
- LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
- This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
- Lantus Versus Levemir Treat-To-Target
- A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
- Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes
- A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
- Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
- Insulin Glargine "All to Target" Trial
- A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
- The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
- A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients
- Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
- The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes
- Lantus in Prediabetes
- Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
- Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin
- Lantus Effect on Myocardial Glucose Metabolism in T2
- LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous
- Perioperative Insulin Glargine Dosing Study
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
- Insulin Glargine in Type 1 Diabetes Mellitus
- Insulin Glargine in Type 2 Diabetes
- Insulin Glargine During and After the Period of Fasting in Ramadan
- A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
- Lantus in the Treatment of Type 1 Diabetes Children
- Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
- LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
- Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
- Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
- Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
- Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
- Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes
- Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
- Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
Clinical trials list
click for details